These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 38903506)

  • 1. Recent advances in understanding the immune microenvironment in ovarian cancer.
    Chen J; Yang L; Ma Y; Zhang Y
    Front Immunol; 2024; 15():1412328. PubMed ID: 38903506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Understanding on Why Ovarian Cancer Is Resistant to Immune Checkpoint Inhibitors.
    Pawłowska A; Rekowska A; Kuryło W; Pańczyszyn A; Kotarski J; Wertel I
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular dynamics of tumor microenvironment driving immunotherapy resistance in non-small-cell lung carcinoma.
    Huang S; Chung JY; Li C; Wu Y; Qiao G; To KF; Tang PM
    Cancer Lett; 2024 Nov; 604():217272. PubMed ID: 39326553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages.
    Song M; Yeku OO; Rafiq S; Purdon T; Dong X; Zhu L; Zhang T; Wang H; Yu Z; Mai J; Shen H; Nixon B; Li M; Brentjens RJ; Ma X
    Nat Commun; 2020 Dec; 11(1):6298. PubMed ID: 33293516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the immune microenvironment for ovarian cancer therapy.
    Blanc-Durand F; Clemence Wei Xian L; Tan DSP
    Front Immunol; 2023; 14():1328651. PubMed ID: 38164130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibitors as mediators for immunosuppression by cancer-associated fibroblasts: A comprehensive review.
    Eskandari-Malayeri F; Rezaei M
    Front Immunol; 2022; 13():996145. PubMed ID: 36275750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade.
    Genova C; Dellepiane C; Carrega P; Sommariva S; Ferlazzo G; Pronzato P; Gangemi R; Filaci G; Coco S; Croce M
    Front Immunol; 2021; 12():799455. PubMed ID: 35069581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives.
    Mao X; Xu J; Wang W; Liang C; Hua J; Liu J; Zhang B; Meng Q; Yu X; Shi S
    Mol Cancer; 2021 Oct; 20(1):131. PubMed ID: 34635121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Complex Tumor Microenvironment in Ovarian Cancer: Therapeutic Challenges and Opportunities.
    Garlisi B; Lauks S; Aitken C; Ogilvie LM; Lockington C; Petrik D; Eichhorn JS; Petrik J
    Curr Oncol; 2024 Jul; 31(7):3826-3844. PubMed ID: 39057155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IR-780 Dye-based Targeting of Cancer-associated Fibroblasts Improves Cancer Immunotherapy by Increasing Intra-tumoral T Lymphocytes Infiltration.
    Yang W; Chen Z; Qu L; Zhang C; Chen H; Zheng J; Chen W; Tan X; Shi C
    Curr Cancer Drug Targets; 2024; 24(6):642-653. PubMed ID: 38310462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic reprogramming and crosstalk of cancer-related fibroblasts and immune cells in the tumor microenvironment.
    Zhu Y; Li X; Wang L; Hong X; Yang J
    Front Endocrinol (Lausanne); 2022; 13():988295. PubMed ID: 36046791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer associated-fibroblast-derived exosomes in cancer progression.
    Li C; Teixeira AF; Zhu HJ; Ten Dijke P
    Mol Cancer; 2021 Dec; 20(1):154. PubMed ID: 34852849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovarian Cancer Immunotherapy: Turning up the Heat.
    Ghisoni E; Imbimbo M; Zimmermann S; Valabrega G
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31208030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Taking a Full Snapshot of Cancer Biology: Deciphering the Tumor Microenvironment for Effective Cancer Therapy in the Oncology Clinic.
    Dzobo K
    OMICS; 2020 Apr; 24(4):175-179. PubMed ID: 32176591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TME-NET: an interpretable deep neural network for predicting pan-cancer immune checkpoint inhibitor responses.
    Ding X; Zhang L; Fan M; Li L
    Brief Bioinform; 2024 Jul; 25(5):. PubMed ID: 39167797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers.
    Pei L; Liu Y; Liu L; Gao S; Gao X; Feng Y; Sun Z; Zhang Y; Wang C
    Mol Cancer; 2023 Feb; 22(1):29. PubMed ID: 36759842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer-Associated Fibroblast Heterogeneity: A Factor That Cannot Be Ignored in Immune Microenvironment Remodeling.
    Chen PY; Wei WF; Wu HZ; Fan LS; Wang W
    Front Immunol; 2021; 12():671595. PubMed ID: 34305902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution of novel immune-checkpoint targets in ovarian cancer tumor microenvironment: A dynamic landscape.
    Blanc-Durand F; Genestie C; Galende EY; Gouy S; Morice P; Pautier P; Maulard A; Mesnage S; Le Formal A; Brizais C; Richardson M; Leary A
    Gynecol Oncol; 2021 Jan; 160(1):279-284. PubMed ID: 33162175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development.
    Yasuda T; Wang YA
    Trends Cancer; 2024 Jul; 10(7):627-642. PubMed ID: 38600020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy and the ovarian cancer microenvironment: Exploring potential strategies for enhanced treatment efficacy.
    Wang ZB; Zhang X; Fang C; Liu XT; Liao QJ; Wu N; Wang J
    Immunology; 2024 Sep; 173(1):14-32. PubMed ID: 38618976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.